CTLA4 and cancer: Indeed, the combination of Ipilimumab (anti-CTLA-4) and Nivolumab (anti-PD-1) significantly enhanced efficacy in metastatic melanoma patients and probably is more effective in other cancers than monotherapies (50, 51).